Effects of hiv medication complexity and depression on adherence to HIV medication

Patient

Volumn 3, Issue 1, 2010, Pages 59-69

  Kumar, Virender ^a   Encinosa, William ^b  

^a WESTAT   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PATIENT COMPLIANCE; PRIORITY JOURNAL; SELF REPORT;

EID: 77953433818     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.2165/11531090-000000000-00000     Document Type: Article

References (42)

1. Garcia de Olalla P, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30 (1): 105-110
2. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16 (7): 1051-1058
3. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338 (13): 853-860
4. Press N, Tyndall MW, Wood E, et al. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002; 31 Suppl. 3: S112-7
5. Bangsberg DR, Perry S, Charlebois ED, et al. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15 (9): 1181-1183
6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133 (1): 21-30
7. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3 (11): e438
8. Chesney MA. The elusive gold standard: future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr 2006; 43 Suppl. 1: S149-55
9. Friedland GH. HIV medication adherence: the intersection of biomedical, behavioral, and social science research and clinical practice. J Acquir Immune Defic Syndr 2006; 43 Suppl. 1: S3-9
10. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults. Neurology 2002; 59 (12): 1944-1950
11. Martin S, Wolters PL, Calabrese SK, et al. The Antiretroviral Regimen Complexity Index: a novel method of quantifying regimen complexity. J Acquir Immune Deficiency Syndr 2007; 45 (5): 535-544
12. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the HER study. J Acquire Immune Defic Syndr 2001; 28 (2): 124-131
13. Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medication in a sample of patients with human immunodeficiency virus infection. Am JMed 2003; 114 (7): 573-580
14. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58 (8): 721-728
15. Turner BJ, Fleishman JA, Enger N, et al. Effects of drug abuse and mental disorders on use and type of anti-retroviral therapy in HIV-infected persons. J Gen Int Med 2001; 16: 625-633
16. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr 2006; 43 (4): 411-417
17. Braithwaite RS, McGinnis KA, Conigliaro J, et al. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res 2005; 29 (7): 1190-1197
18. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002; 17 (10): 756-765
19. Power R, Koopman C, Volk J, et al. Social support, substance use, and denial in relationship to antiretroviral treatment adherence among HIV-infected persons. AIDS Patient Care STDS 2003; 17 (5): 245-252
20. Murphy WR, Tonigan JS, Longabaugh R. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 2005; 159: 764-770
21. Gonzalez JS, Penedo FJ, Antoni MH, et al. Social support, positive states of mind, HIV treatment adherence in men and women living with HIV/AIDS. Health Psychol 2004; 23: 413-418
22. Bozzette SA, Berry SH, Duan N, et al. The care of HIVinfected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998; 339 (26): 1897-1904
23. Frankel MR, Shapiro MF, Duan N, et al. National probability samples in studies of low-prevalence diseases: part II. Designing and implementing the HIV cost and services utilization study sample. Health Serv Res 1999; 34 (5 Pt 1): 969-992
24. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43: 939-941
25. Shuter J, Sarlo JA, Kanmaz TJ, et al. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007; 45 (1): 4-8
26. Shapiro MF, Berk ML, Berry SH, et al. National probability samples in studies of low-prevalence diseases: part I. Perspectives and lessons from the HIV cost and services utilization study. Health Serv Res 1999; 34 (5 Pt 1): 951-968
27. Redbook. Montvale (NJ): Medical Economics Company, 2006
28. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Rockville (MD): Department of Health and Human Services, 2007 Dec 1 [online]. Available from URL: http://aidsinfo.nih.gov/con tentfiles/ AdultandAdolescentGL.pdf [Accessed 2008 Aug 1]
29. Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002 May 17; 51 (RR-7): 1-55
30. Report of the NIH Panel to Define Principles of Therapy of HIV Infection. MMWR Recomm Rep 1998; 47 (RR-5): 1-41
31. Alcoholic beverages. In: US DHHS & US Department of Agriculture, editors. Dietary guidelines for Americans. Washington, DC: US Government Printing Office, 2005: 43-46
32. National Institute of Alcohol Abuse and Alcoholism. NIAAA council approves definition of binge drinking. NIAAA Newsletter 2004; 3 [online]. Available from URL: http://pubs.niaaa.nih.gov/publications/Newsletter/winter 2004/Newsletter-Number3.pdf [Accessed 2007 Oct 16]
33. Hays R, Spritzer KL, McCaffrey D, et al. The HCSUS measures of health-related quality of life. Santa Monica (CA): RAND, 1998 [online]. Available from URL: http:// www.rand.org/pubs/drafts/2008/DRU1897.pdf [Accessed 2009 Jun 12]
34. Berry SH, Brown JA, Athey L, et al. HCSUS baseline patient questionnaire documentation. Santa Monica (CA): RAND, 1998
35. Stata Statistical Software. Reference manual K-Q: release 9 (340-351). College Station (TX): StataCorp LP, 2005
36. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999; 13 (9): 1099-1107
37. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 34 (8): 1115-1121
38. Aberg JA, Gailant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with HIV: recommendations of the HIV Medicine Association of the Infectious Disease Society of America. Clin Infect Dis 2004 Sept 1; 39 (5): 609-629
39. Office of the Medical Director, New York State Department of Health AIDS Institute in collaboration with Johns Hopkins University Division of Infectious Diseases. Adherence to antfiretroviral therapy among substance abusers [online]. Available from URL: http://www.hivguidelines. org [Accessed 2009 Aug 13]
40. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16 (5): 767-774
41. Yun LWH, Maravi M, Kobayashi JS, et al. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr 2005; 38 (4): 432-438
42. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84 (2): 188-194